NEW YORK, April 11, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
Nordion Inc. (NYSE: NDZ), Abbott Laboratories (NYSE: ABT), Covidien
plc (NYSE: COV), DaVita HealthCare Partners Inc. (NYSE: DVA), and
Sirona Dental Systems Inc. (NASDAQ: SIRO). Private wealth members
receive these notes ahead of publication. To reserve complementary
membership, limited openings are available at:
http://www.AnalystsReview.com/register
--
Nordion Inc. Analyst Notes
On March 28, 2014, Nordion Inc.
(Nordion) announced that it has entered into a definitive agreement
to be acquired by Sterigenics, in a transaction valued at
approximately $727 million. The
Company informed that pursuant to the terms of this agreement,
shareholders will receive an aggregate cash consideration of
$11.75 per share. Additionally, the
Company stated that upon closing of this transaction, Nordion will
operate as a standalone company within Sterigenics and will
continue to operate with its own name. The Company informed that
the transaction will be funded using a combination of new debt
facilities and equity financing, both of which are fully committed,
Sterigenics' cash on hand, and a portion of Nordion's cash on hand.
Commenting on the acquisition, Steve
West, CEO of Nordion, stated, "This transaction delivers
value to our shareholders and is a good strategic fit for Nordion.
We believe this partnership is beneficial to Nordion's employees
and our customers, as Nordion and Sterigenics combine their global
expertise, industry knowledge and the same focus on high quality
standards and values. This transaction also marks the successful
completion of Nordion's strategic review." The full analyst notes
on Nordion Inc. are available to download free of charge at:
http://www.AnalystsReview.com/04112014/NDZ/report.pdf
--
Abbott Laboratories Analyst Notes
On March 28, 2014, Abbott
Laboratories (Abbott) announced that the U.S. Food and Drug
Administration (FDA) has approved its Supera® Peripheral Stent
System to treat people with blocked blood vessels in the upper leg
caused by peripheral artery disease (PAD). According to the
Company, PAD occurs when fat and cholesterol buildup causes
arteries outside of the heart to narrow, which reduces blood flow
to parts of the body, most commonly the legs. Commenting on the
approval, Chuck Foltz, Senior Vice
President, Vascular, Abbott, said "FDA approval of the Supera stent
provides an additional treatment option that can make a positive
impact on the lives of people suffering from peripheral artery
disease. FDA approval of the Supera stent gives Abbott rapid entry
into one of the fastest-growing segments of the peripheral stent
market, providing Abbott with one of the most comprehensive and
competitive peripheral technology portfolios in the industry." The
full analyst notes on Abbott Laboratories are available to download
free of charge at:
http://www.AnalystsReview.com/04112014/ABT/report.pdf
--
Covidien plc Analyst Notes
On March 28, 2014, Covidien plc
(Covidien) announced that it has partnered with the AORN Foundation
on an initiative that will provide nurse leaders with a core set of
financial and management tools to complement their clinical
expertise. According to the Company, the new AORN Emerging Leaders
educational initiative will comprise five day-long seminars
focusing on leadership development and financial concepts necessary
for managing the overall performance of perioperative services.
Matt Gattuso, President of health
systems at Covidien and an AORN Foundation Board Member, stated,
"Nurses are on the frontlines of care, and increasingly find
themselves at the intersection of improving patient outcomes in a
lower cost environment. Covidien is committed to increasing access
to quality health care for all, and we believe that improving the
financial and managerial skills and abilities of nurse leaders will
be a win-win for patient care." The full analyst notes on Covidien
plc are available to download free of charge at:
http://www.AnalystsReview.com/04112014/COV/report.pdf
--
DaVita HealthCare Partners Inc. Analyst Notes
On March 18, 2014, DaVita
HealthCare Partners Inc. (DaVita) announced that Javier Rodriguez has transitioned from President
to CEO of DaVita's Kidney Care Division. According to the Company,
Kent Thiry will remain CEO of DaVita
as well as Co-Chairman of the Board of Directors. Commenting on
this transition, Thiry stated, "Javier is a dynamic, decisive
leader who has played a key role in DaVita's success. He's been
with me since my first day as CEO nearly 15 years ago and I
couldn't be happier or prouder to see him take over leadership of
our kidney care business." The full analyst notes on DaVita
HealthCare Partners Inc. are available to download free of charge
at:
http://www.AnalystsReview.com/04112014/DVA/report.pdf
--
Sirona Dental Systems Inc. Analyst Notes
On March 24, 2014, Sirona Dental
Systems Inc. (Sirona) reported that it has once again received the
renowned iF product design award. According to the
Company, Johannes Krug, Product
Manager Lab hardware at Sirona, accepted the coveted award at BMW
Welt in Munich. Commenting on the
recognition, Krug stated, "Good design is not an end in itself;
rather it makes an essential contribution to the fact that our
products are easier to handle. The user-friendliness and quality of
our products is confirmed again and again with every design award."
The full analyst notes on Sirona Dental Systems Inc. are available
to download free of charge at:
http://www.AnalystsReview.com/04112014/SIRO/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Nidhi Vatsal, CFA, has only reviewed the information
provided by Analysts Review in this article or report according to
the Procedures outlined by Analysts Review. Analysts Review is not
entitled to veto or interfere in the application of such procedures
by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
http://AnalystsReview.com
SOURCE Analysts Review